ILARIS 150MG VIAL

  • اسم المستحضر : ILARIS 150MG VIAL
  • اسم المصنع : Novartis Pharma AG, Switzerland
  • التصنيف : Import Product
  • الوكيل / الموزع : GrandPharm for Pharmaceuticals Investment Co
  • الشكل الصيدلاني : Powder for solution for subcutaneous Injection
  • المكونات الفعالة : One vial contains: Canakinumab 150mg
  • يستخدم لـ : Ilaris (canakinumab) is an interleukin-1 beta blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults and children aged 2 years and older, including: -Familial Cold Autoinflammatory Syndrome (FCAS)/ Familial Cold Urticaria (FCU) -Muckle-Wells Syndrome (MWS) -Neonatal-Onset Multisystem Inflammatory Disease (NOMID)/ Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) The pivotal study was performed in patients with MWS. Experience in FCAS/FCU and NOMID/CINCA, especially in paediatric patients, is still very limited. As a rule, the diagnosis should be confirmed by gene mutation tests (NLRP3/CIAS1). Clinical experience with Ilaris is limited in patients without a confirmed mutation in the NLRP3/CIAS1 gene. Treatment should only be carried out by specialists with experience in the clinical treatment of CAPS. Patient details must be entered into a CAPS registry specifically designed for Ilaris. Tumor Necrosis Factor receptor Associated Periodic Syndrome (TRAPS) Ilaris is indicated for the treatment of patients with Tumor Necrosis Factor receptor Associated Periodic Syndrome (TRAPS) Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) Ilaris is indicated for the treatment of patients with Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) Familial Mediterranean Fever (FMF) Ilaris is indicated for the treatment of patients with Familial Mediterranean Fever (FMF) in whom conventional therapy is contraindicated, is not tolerated or does not provide an adequate response despite the highest tolerable dose being administered Ilaris is also indicated for the treatment of: Systemic Juvenile Idiopathic Arthritis (SJIA) Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to prior treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be used as monotherapy or in combination with methotrexate.
  • رقم التسجيل : 88/6578/00
  • تاريخ التسجيل : 28-03-2018
  • تاريخ انتهاء التسجيل : 28-03-2023

Please Wait